Confucius Plaza Medical Laboratory Corp

Confucius Plaza Medical Laboratory Corp was paid $12.23M by Medicaid between Dec 2020 and Aug 2023, across 10 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#27 of 122

Median peer was paid$1.29M

This provider vs. median9.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	173	$2K
2021	65,173	$1.93M
2022	265,097	$6.94M
2023	149,461	$3.36M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	56%	129,833	89,021	$6.79M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	122,676	85,449	$2.10M
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	17%	77,214	48,119	$2.10M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	5.2%	117,411	80,416	$632K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	3.4%	17,059	6,434	$418K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	1.6%	14,686	8,405	$191K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	95	93	$1K
86769		<1%	50	49	$1K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	861	725	$675.00
99080		0%	19	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRIZZO, ERLINDA (MANAGER)